Director Dealing

RNS Number : 9507V

Scancell Holdings Plc

12 August 2020

 

12 August 2020

Scancell Holdings plc

("Scancell" or the "Company")

Director Dealing

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer, announces the following subscriptions for shares by Directors in its recent Open Offer on the same terms as other investors:

Lindy Durrant, Chief Scientific Officer, subscribed for 130,649 ordinary shares of 0.1 pence each in Scancell Holdings plc ("Ordinary Shares") at a price of 5.5 pence per Ordinary Share. Following the transaction Lindy Durrant has a total interest of 10,570,392 Ordinary Shares, representing 1.68% of the total voting rights in the Company.

Sally Adams, Development Director, subscribed for 7,705 Ordinary Shares at a price of 5.5 pence per Ordinary Share. Following the transaction Sally Adams has a total interest of 69,623 Ordinary Shares, representing 0.01% of the total voting rights in the Company.

  Capitalised terms used in this announcement have the meaning as defined in the Placing Launch Announcement released at 7.00am on 22 July 2020 unless otherwise stated.

For the purposes of MAR and Article 2 of Commission Implementing Regulation (EU) 2016/1055, the person responsible for arranging for the release of this announcement on behalf of the Company is Cliff Holloway, Chief Executive Officer.

- ENDS -

For further information, please contact:

Scancell Holdings plc Dr John Chiplin, Executive Chairman Dr Cliff Holloway, CEO [phone] Panmure Gordon (UK) Limited Freddy Crossley/Emma Earl (Corporate Finance) [phone] James Stearns (Corporate Broking) FTI Consulting Simon Conway/Natalie Garland-Collins [phone]

Notes for Editors

About Scancell

Scancell is developing novel immunotherapies for the treatment of cancer based on its technology platforms, ImmunoBody^®, Moditope^® and AvidiMab^TM, with four products in multiple cancer indications and development of a vaccine for COVID-19.

ImmunoBody® vaccines target dendritic cells and stimulate both CD4 and CD8 T cells with the ability to identify, target and eliminate cancer cells. These cancer vaccines have the potential to be used as monotherapy or in combination with checkpoint inhibitors and other agents. The Directors believe that this platform has the potential to enhance tumour destruction, prevent disease recurrence and extend survival.

· SCIB1, Scancell's lead product, is being developed for the treatment of metastatic melanoma. In a Phase 1/2 clinical trial, survival with SCIB1 treatment appears superior to historical survival rates, with 14 of 16 resected patients receiving 2-4 mg doses of SCIB1 surviving for more than five years (as reported in February 2018).

· SCIB2 is being developed for the treatment of non-small cell lung cancer and other solid tumours. Scancell has entered into a clinical development partnership with Cancer Research UK (CRUK) for SCIB2.

DNA vaccine against COVID-19: As research data emerges, it is becoming increasingly clear that the induction of potent and activated T cells may play a critical role in the development of long-term immunity and clearance of virus-infected cells. Initial research is underway and subject to funding being secured, Scancell anticipates initiating a Phase 1 clinical trial known as COVIDITY.

Moditope® represents a completely new class of potent and selective immunotherapy agents based on stress-induced post-translational modifications (siPTM). Examples of such modifications are citrullination, an enzyme-based conversion of arginine to citrulline, and homocitrullination (or carbamylation), in which lysine residues are converted to homocitrulline. Expression of peptides containing these modifications have been demonstrated to induce potent CD4 cytotoxic T-cells to eliminate cancer. Previous pre-clinical studies have demonstrated that conjugation of these Moditope® peptides to Amplivant® enhances anti-tumour immune responses 10-100 fold and resulted in highly efficient tumour eradication, including protection against tumour recurrence.

· Modi-1 consists of two citrullinated vimentin peptides and one citrullinated enolase peptide each conjugated to Amplivant®. Vimentin and enolase peptides are highly expressed in triple negative breast, ovarian, head and neck, and renal cancer, as well as many other cancers. The Company continues to progress the Modi-1 Phase 1/2 clinical trial for regulatory submission to start the planned clinical study in the UK in the first half of 2021.

AvidiMab™ has broad potential to increase the avidity or potency of any therapeutic monoclonal antibody (mAb) including those being developed for autoimmune diseases, as well as cancer. Scancell's development pipeline includes mAbs against specific tumour-associated glycans (TaGs) with superior affinity and selectivity profiles, that have now been further engineered using the Company's AvidiMab™ technology; this confers the Scancell anti-TaG mAbs with the ability to directly kill tumour cells. The Company has entered into three non-exclusive research agreements with leading antibody technology companies to evaluate the Company's anti-TaG mAbs including those enhanced with the AvidiMab™ technology.

For further details, please see the Company's website:  www.scancell.co.uk

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	L indy Durrant Sally Adams
2	Reason for the notification
a)	Position/status	Chief Scientific Officer Development Director
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Scancell Holdings plc
b)	LEI	2138008RXEG856SNP666
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary shares of 0.1 pence each
	Identification code	GB00B63D3314
b)	Nature of the transaction	Subscription for Open Offer shares
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			5.5p	130,649
			5.5p	7,705
d)	Aggregated information
	- Aggregated volume	- 138,354
	- Price	- 5.5p
e)	Date of the transaction	12 August 2020
f)	Place of the transaction	London Stock Exchange, AIM

 

END

 

 

DSHEAFPAFSSEEFA